Edition:
United States

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

15.17CNY
20 Apr 2018
Change (% chg)

¥-0.80 (-5.01%)
Prev Close
¥15.97
Open
¥15.85
Day's High
¥15.99
Day's Low
¥15.15
Volume
10,518,887
Avg. Vol
9,075,485
52-wk High
¥16.70
52-wk Low
¥10.24

Select another date:

Wed, Jan 31 2018

BRIEF-Zhejiang Hisun Pharmaceutical to swing to profit in FY 2017

* Sees to swing to net profit at 10 million yuan to 15 million yuan in FY 2017 versus net loss at 94.4 million yuan year ago

BRIEF-Zhejiang Hisun Pharmaceutical and unit obtain high-tech enterprise recognition and to enjoy tax preference

* Says it and unit were recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years

BRIEF-Zhejiang Hisun Pharma Adjusts Private Placement Plan, To Raise Up To 940.9 Mln Yuan

* SAYS IT ADJUSTS A-SHARE PRIVATE PLACEMENT PLAN, TO RAISE UP TO 940.9 MILLION YUAN ($144.66 million) Source text in Chinese: http://bit.ly/2zLTZwE Further company coverage: ($1 = 6.5040 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume after Pfizer exited China JV

* SAYS SHARE TRADE TO RESUME ON NOV 29 AFTER PFIZER EXITED CHINA JOINT VENTURE WITH THE COMPANY Source text in Chinese: http://bit.ly/2iZ534b Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Zhejiang Hisun Pharmaceutical passes FDA approval

* Says it received approval for a kind of tablet from U.S Food and Drug Administration

BRIEF-Zhejiang Hisun Pharmaceutical to issue up to 3.0 bln yuan commercial paper

* Says it plans to issue up to 3.0 billion yuan ($452.59 million) ultra-short commercial paper

BRIEF-Zhejiang Hisun Pharmaceutical unit says product gets FDA approval

* Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration

Pfizer exits China joint venture for generic drugs

Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

Pfizer exits China joint venture for generic drugs

Nov 10 Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

Select another date: